Terms: = Ovarian cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
468 results:
1. The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.
Liu Y; Geng F; Zhang H; Xue J; Chu R
World J Surg Oncol; 2024 Jan; 22(1):37. PubMed ID: 38287354
[TBL] [Abstract] [Full Text] [Related]
2. Reduced healthcare access contributes to delay of care in endometrial cancer.
Fife AJ; Najor AJ; Aspir TB; Haines KE; Vilardo NA; Isani SS; Cowan M; Gressel GM; Ye KQ; Nevadunsky NS; Kuo DY; Lin KY
Gynecol Oncol; 2024 Mar; 182():115-120. PubMed ID: 38262233
[TBL] [Abstract] [Full Text] [Related]
3. Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer.
Huang Y; Qin T; Yang M; Liu Z
Medicine (Baltimore); 2023 Dec; 102(50):e36373. PubMed ID: 38115303
[TBL] [Abstract] [Full Text] [Related]
4. Rationale and methodologic Approach for Assessing ovarian cancer treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.
Ng D; Ross W; Traverso-Ortiz M; Rim SH; Wike JM; Moore AR;
J Registry Manag; 2023; 50(3):85-91. PubMed ID: 37941740
[TBL] [Abstract] [Full Text] [Related]
5. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM; O'Malley DM; Monk BJ; Coleman RL; Gaillard S; Adams S; Duska LR; Dalton H; Holloway RW; Huang M; Chon HS; Cloven NG; ElNaggar AC; O'Cearbhaill RE; Waggoner S; Tarkar A; Striha A; Nelsen LM; Baines A; Samnotra V; Konstantinopoulos PA
Gynecol Oncol; 2023 Nov; 178():161-169. PubMed ID: 37890345
[TBL] [Abstract] [Full Text] [Related]
6. Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC).
Kim YB; Byun HK; Wee CW; Kim H; Kim S; Yang G; Kim J; Park SJ; Lee JY
BMC Cancer; 2023 Oct; 23(1):1014. PubMed ID: 37864152
[TBL] [Abstract] [Full Text] [Related]
7. treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract] [Full Text] [Related]
8. All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
Jorgensen K; Denham C; Kanbergs A; Wu CF; Nitecki R; Agusti N; Meernik C; Melamed A; Rauh-Hain JA
Gynecol Oncol; 2023 Nov; 178():60-68. PubMed ID: 37801736
[TBL] [Abstract] [Full Text] [Related]
9. Dose reduction of olaparib in older patients: Insights from an analysis of a National Database in Japan.
Sato M; Goto T
J Obstet Gynaecol Res; 2023 Dec; 49(12):2889-2893. PubMed ID: 37786354
[TBL] [Abstract] [Full Text] [Related]
10. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial cancer.
Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; Mirza MR; Makker V;
J Clin Oncol; 2023 Dec; 41(35):5400-5410. PubMed ID: 37669480
[TBL] [Abstract] [Full Text] [Related]
11. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
J Gynecol Oncol; 2023 Sep; 34(5):e85. PubMed ID: 37593813
[TBL] [Abstract] [Full Text] [Related]
12. A Systematic Review of Surgical Management Strategies in the treatment of Peritoneal Carcinomatosis of Neuroendocrine Origin.
Fallows M; Samant A; Wilson H; Mirnezami R
Curr Oncol; 2023 Jul; 30(7):6316-6329. PubMed ID: 37504326
[TBL] [Abstract] [Full Text] [Related]
13. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract] [Full Text] [Related]
14. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
Hagio K; Kikuchi J; Takada K; Tanabe H; Sugiyama M; Ohhara Y; Amano T; Yuki S; Komatsu Y; Osawa T; Hatanaka KC; Hatanaka Y; Mitamura T; Yabe I; Matsuno Y; Manabe A; Sakurai A; Ishiguro A; Takahashi M; Yokouchi H; Naruse H; Mizukami Y; Dosaka-Akita H; Kinoshita I
Cancer Sci; 2023 Aug; 114(8):3385-3395. PubMed ID: 37208840
[TBL] [Abstract] [Full Text] [Related]
15. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
[TBL] [Abstract] [Full Text] [Related]
16. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to ovarian cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract] [Full Text] [Related]
17. HYPERPLASIA OF THE FEMALE REPRODUCTIVE ORGANS IN UKRAINE.
Salmanov AG; Artyomenko V; Hladenko SY; Koctjuk IM; Marchenko AO; Tolstanova GO; Korniyenko SM
Wiad Lek; 2023; 76(3):467-473. PubMed ID: 37057766
[TBL] [Abstract] [Full Text] [Related]
18. Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.
Wimberger P; Pfisterer J; du Bois A; Hilpert F; Kerkmann M; Sehouli J; Mahner S; de Gregorio N; Hanker L; Heitz F; Marmé F; Woelber L; Holtmann L; Elser G; Harter P;
Int J Gynecol Cancer; 2023 Jul; 33(7):1083-1089. PubMed ID: 37001891
[TBL] [Abstract] [Full Text] [Related]
19. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
Jorgensen K; Melamed A; Wu CF; Nitecki R; Pareja R; Fagotti A; Schorge JO; Ramirez PT; Rauh-Hain JA
Gynecol Oncol; 2023 May; 172():130-137. PubMed ID: 36977622
[TBL] [Abstract] [Full Text] [Related]
20. Assessment of a Peer Physician Coaching Partnership Between a Designated cancer Center Genetics Service and a Community cancer Network Hospital.
Santos LG; Buzdnitskaya T; Rolf BA; Souza W; Sienko M; Ruiz-Bonilla JA; Shah B; Jewell P; Jensen L; Horike-Pyne M; Elrod JA; Crews J; Laurino M; Weeks KA; Dubard-Gault ME
JAMA Netw Open; 2023 Mar; 6(3):e231723. PubMed ID: 36877518
[TBL] [Abstract] [Full Text] [Related]
[Next]
